Literature DB >> 32014869

Fibroblast Heterogeneity in the Pancreatic Tumor Microenvironment.

Erin Helms1, M Kathrina Onate1, Mara H Sherman2,3.   

Abstract

The poor prognosis for patients with pancreatic ductal adenocarcinoma (PDAC) impels an improved understanding of disease biology to facilitate the development of better therapies. PDAC typically features a remarkably dense stromal reaction, featuring and established by a prominent population of cancer-associated fibroblasts (CAF). Genetically engineered mouse models and increasingly sophisticated cell culture techniques have demonstrated important roles for fibroblasts in PDAC progression and therapy response, but these roles are complex, with strong evidence for both tumor-supportive and tumor-suppressive or homeostatic functions. Here, we review the recent literature that has improved our understanding of heterogeneity in fibroblast fate and function in this disease including the existence of distinct fibroblast populations, and highlight important avenues for future study. SIGNIFICANCE: Although the abundant stromal reaction associated with pancreatic cancer has long been appreciated, the functions of the CAF cells that establish this stromal reaction remain unclear. An improved understanding of the transcriptional and functional heterogeneity of pancreatic CAFs, as well as their tumor-supportive versus tumor-suppressive capacity, may facilitate the development of effective therapies for this disease. ©2020 American Association for Cancer Research.

Entities:  

Year:  2020        PMID: 32014869     DOI: 10.1158/2159-8290.CD-19-1353

Source DB:  PubMed          Journal:  Cancer Discov        ISSN: 2159-8274            Impact factor:   39.397


  71 in total

1.  Cancer associated fibroblast: Mediators of tumorigenesis.

Authors:  Jennifer Alexander; Edna Cukierman
Journal:  Matrix Biol       Date:  2020-05-22       Impact factor: 11.583

Review 2.  Advances in CAR-T Cell Genetic Engineering Strategies to Overcome Hurdles in Solid Tumors Treatment.

Authors:  Alain E Andrea; Andrada Chiron; Sarah Mallah; Stéphanie Bessoles; Guillaume Sarrabayrouse; Salima Hacein-Bey-Abina
Journal:  Front Immunol       Date:  2022-02-08       Impact factor: 7.561

Review 3.  Metabolic reprogramming by driver mutation-tumor microenvironment interplay in pancreatic cancer: new therapeutic targets.

Authors:  Henriette Berg Andersen; Renata Ialchina; Stine Falsig Pedersen; Dominika Czaplinska
Journal:  Cancer Metastasis Rev       Date:  2021-12-02       Impact factor: 9.264

Review 4.  Clinical and therapeutic relevance of cancer-associated fibroblasts.

Authors:  Yang Chen; Kathleen M McAndrews; Raghu Kalluri
Journal:  Nat Rev Clin Oncol       Date:  2021-09-06       Impact factor: 66.675

Review 5.  Harnessing metabolic dependencies in pancreatic cancers.

Authors:  Joel Encarnación-Rosado; Alec C Kimmelman
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2021-03-19       Impact factor: 46.802

6.  Macropinocytosis in Cancer-Associated Fibroblasts Is Dependent on CaMKK2/ARHGEF2 Signaling and Functions to Support Tumor and Stromal Cell Fitness.

Authors:  Yijuan Zhang; M Victoria Recouvreux; Michael Jung; Koen M O Galenkamp; Yunbo Li; Olga Zagnitko; David A Scott; Andrew M Lowy; Cosimo Commisso
Journal:  Cancer Discov       Date:  2021-03-02       Impact factor: 39.397

Review 7.  Pancreatic Cancer Immuno-oncology in the Era of Precision Medicine.

Authors:  Samarth Hegde
Journal:  Indian J Surg Oncol       Date:  2020-08-25

Review 8.  microRNA-based diagnostic and therapeutic applications in cancer medicine.

Authors:  Lorenzo F Sempere; Asfar S Azmi; Anna Moore
Journal:  Wiley Interdiscip Rev RNA       Date:  2021-05-17       Impact factor: 9.957

9.  Cx43 phosphorylation sites regulate pancreatic cancer metastasis.

Authors:  Joell L Solan; Sunil R Hingorani; Paul D Lampe
Journal:  Oncogene       Date:  2021-02-18       Impact factor: 9.867

10.  Single-cell analysis of pancreatic ductal adenocarcinoma identifies a novel fibroblast subtype associated with poor prognosis but better immunotherapy response.

Authors:  Yu Wang; Yiyi Liang; Haiyan Xu; Xiao Zhang; Tiebo Mao; Jiujie Cui; Jiayu Yao; Yongchao Wang; Feng Jiao; Xiuying Xiao; Jiong Hu; Qing Xia; Xiaofei Zhang; Xujun Wang; Yongwei Sun; Deliang Fu; Lei Shen; Xiaojiang Xu; Jing Xue; Liwei Wang
Journal:  Cell Discov       Date:  2021-05-25       Impact factor: 10.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.